A Study to Evaluate of PM8002 Combined With PM1009 in Patients With First-line HCC

NCT06584071 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

NOT_YET_RECRUITING

Status

140

Enrollment

INDUSTRY

Sponsor class

Conditions

HCC
Liver Cancer

Interventions

DRUG: PM8002
DRUG: PM1009
DRUG: atezolizumab
DRUG: bevacizumab

Sponsor

Biotheus Inc.